Bristol-Myers Squibb Company (BMY)
| Market Cap | 111.95B +24.7% |
| Revenue (ttm) | 48.48B +1.8% |
| Net Income | 7.28B +34.3% |
| EPS | 3.57 +33.7% |
| Shares Out | 2.04B |
| PE Ratio | 16.01 |
| Forward PE | 9.34 |
| Dividend | $2.52 (4.60%) |
| Ex-Dividend Date | Apr 2, 2026 |
| Volume | 9,449,575 |
| Open | 57.40 |
| Previous Close | 57.18 |
| Day's Range | 54.71 - 57.45 |
| 52-Week Range | 42.52 - 62.89 |
| Beta | 0.24 |
| Analysts | Hold |
| Price Target | 63.08 (+15.07%) |
| Earnings Date | Apr 30, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $63.08, which is an increase of 15.07% from the latest price.
News
Bristol Myers: Opdivo in combination with AVD receives expanded EU label
Bristol Myers (BMY) Squibb announced that the European Commission has approved Opdivo in combination with doxorubicin, vinblastine and dacarbazine for the treatment of adult and adolescent patients 12...
Bristol Myers says FDA accepts sNDA for Camzyos
Bristol Myers (BMY) Squibb announced the U.S. Food and Drug Administration FDA accepted a supplemental New Drug Application for Camzyos as a potential treatment for adolescents with symptomatic obstru...
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--US FDA Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM.
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #HodgkinLymphoma--BMS Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Ly...
BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial
BioNTech SE (BNTX) and Bristol Myers Squibb Company (BMY) announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific...
C4 Therapeutics jumps after Bristol Myers myeloma data
Shares of C4 Therapeutics (CCCC) are up 19%, or 70c, to $4.36 in midday trading after Bristol Myers (BMY) announced positive Phase 3 multiple myeloma data.
Bristol Myers says CELMoD mezigdomide reduces risk of disease progression by 52%
Bristol Myers (BMY) Squibb announced late-breaking results from the Phase 3 SUCCESSOR-2 trial of CELMoD mezigdomide in combination with carfilzomib and dexamethasone versus carfilzomib and dexamethaso...
Bristol Myers drug delays myeloma progression in hard to treat patients
Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not respon...
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in.
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline.
BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees
Bristol Myers Squibb ($BMY), a large U.S. drug firm focused on cancer, blood, and immune disease drugs, is teaming up with Anthropic to bring its Claude AI model to more…
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delive...
Bristol Myers announces strategic agreement with Anthropic
Bristol Myers (BMY) Squibb announced a strategic agreement with Anthropic to deploy Claude across the company’s research, clinical development, manufacturing, commercial, and corporate functions. The ...
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across.
Bristol-Myers Squibb Brings Anthropic's Claude to 30,000 of Its Staff
The deal helps solidify Anthropic's commitment to the life sciences sector as it targets more enterprise clients.
US Supreme Court rebuffs pharma challenge to Biden-era drug price
The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that...
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
Bristol Myers Squibb this week announced a partnership with Hengrui Pharma to develop drugs together. American and European biopharmaceutical companies are increasingly looking to China for their next...
Bristol-Myers Squibb Company Transcript: Bank of America Global Healthcare Conference 2026
Strong growth in the portfolio is driven by new launches and robust pipeline progress, with double-digit gains in key products and multiple catalysts expected through 2030. Strategic business development and innovation in oncology, neuroscience, and cardiovascular therapies position the company for sustained leadership.
Tempus AI announces strategic collaboration with Bristol Myers
Tempus AI (TEM) announced a new initiative with Bristol Myers Squibb (BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial de...
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE...
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Pr...
Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up
U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals, in a deal that could worth more than $15 bill...
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to ad...
China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
China's Jiangsu Hengrui Pharmaceuticals said on Tuesday it has struck global strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb to develop 13 early‑stage on...